A hydrogel-based tumor model for the evaluation of nanoparticle-based cancer therapeutics
Source abstract
Abstract
Three-dimensional (3D) tissue-engineered tumor models have the potential to bridge the gap between monolayer cultures and patient-derived xenografts for the testing of nanoparticle (NP)-based cancer therapeutics. In this study, a hydrogel-derived prostate cancer (PCa) model was developed for the in vitro evaluation of doxorubicin (Dox)-loaded polymer NPs (Dox-NPs). The hydrogels were synthesized using chemically modified hyaluronic acid (HA) carrying acrylate groups (HA-AC) or reactive thiols (HA-SH). The crosslinked hydrogel networks exhibited an estimated pore size of 70-100 nm, similar to the spacing of the extracellular matrices (ECM) surrounding tumor tissues. LNCaP PCa cells entrapped in the HA matrices formed distinct tumor-like multicellular aggregates with an average diameter of 50 μm after 7 days of culture. Compared to cells grown on two-dimensional (2D) tissue culture plates, cells from the engineered tumoroids expressed significantly higher levels of multidrug resistance (MDR) proteins, including multidrug resistance protein 1 (MRP1) and lung resistance-related protein (LRP), both at the mRNA and the protein levels. Separately, Dox-NPs with an average diameter of 54 ± 1 nm were prepared from amphiphilic block copolymers based on poly(ethylene glycol) (PEG) and poly(ε-caprolactone) (PCL) bearing pendant cyclic ketals. Dox-NPs were able to diffuse through the hydrogel matrices, penetrate into the tumoroid and be internalized by LNCaP PCa cells through caveolae-mediated endocytosis and macropinocytosis pathways. Compared to 2D cultures, LNCaP PCa cells cultured as multicellular aggregates in HA hydrogel were more resistant to Dox and Dox-NPs treatments. Moreover, the NP-based Dox formulation could bypass the drug efflux function of MRP1, thereby partially reversing the resistance to free Dox in 3D cultures. Overall, the engineered tumor model has the potential to provide predictable results on the efficacy of NP-based cancer therapeutics.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · 3D Printing in Biomedical Research · Tissue Engineering and Regenerative Medicine
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (62)
Show source-provided references
1. Nanocarriers as an emerging platform for cancer therapy10.1038/nnano.2007.387 ↗
2. Active targeting schemes for nanoparticle systems in cancer therapeutics10.1016/j.addr.2008.08.005 ↗
3. Nanomedicine: current status and future prospects10.1096/fj.04-2747rev ↗
4. Targeted polymeric therapeutic nanoparticles: design, development and clinical translation10.1039/c2cs15344k ↗
5. Delivering nanomedicine to solid tumors10.1038/nrclinonc.2010.139 ↗
6. Nanopreparations to overcome multidrug resistance in cancer10.1016/j.addr.2013.08.004 ↗
7. Doxorubicin delivery to 3D multicellular spheroids and tumors based on boronic acid-rich chitosan nanoparticles10.1016/j.biomaterials.2013.03.008 ↗
8. 3-D tissue culture systems for the evaluation and optimization of nanoparticle-based drug carriers10.1021/bc800233a ↗
9. Photoswitchable nanoparticles for triggered tissue penetration and drug delivery10.1021/ja211888a ↗
10. Cell and environment interactions in tumor microregions: the multicell spheroid model10.1126/science.2451290 ↗
11. Involvement of hypoxia-inducible factor-1-alpha in multidrug resistance induced by hypoxia in HepG2 cells
12. Effect of environmental factors on chemoresistance of HepG2 cells by regulating hypoxia-inducible factor-1 alpha
13. Expression of multidrug resistance proteins in prostate cancer is related with cell sensitivity to chemotherapeutic drugs10.1002/pros.20991 ↗
14. Development of an intrinsic P-glycoprotein-mediated doxorubicin resistance in quiescent cell layers of large, multicellular prostate tumor spheroids10.1002/(SICI)1097-0215(19980316)75:6<855::AID-IJC7>3.0.CO;2-U ↗
15. Role of hypoxia and glycolysis in the development of multi-drug resistance in human tumor cells and the establishment of an orthotopic multi-drug resistant tumor model in nude mice using hypoxic pre-conditioning
16. Low external pH and osmotic shock increase the expression of human MDR protein10.1021/bi00189a027 ↗
17. Recreating the tumor microenvironment in a bilayer, hyaluronic acid hydrogel construct for the growth of prostate cancer spheroids10.1016/j.biomaterials.2012.08.061 ↗
18. 3D in vitro bioengineered tumors based on collagen I hydrogels10.1016/j.biomaterials.2011.07.001 ↗
19. The enhancement of cancer stem cell properties of MCF-7 cells in 3D collagen scaffolds for modeling of cancer and anti-cancer drugs10.1016/j.biomaterials.2011.10.056 ↗
20. Dense type I collagen matrices that support cellular remodeling and microfabrication for studies of tumor angiogenesis and vasculogenesis in vitro10.1016/j.biomaterials.2010.07.072 ↗
21. Can cancer be reversed by engineering the tumor microenvironment?
22. Suppression of oncogenic properties of c-Myc by LKB1-controlled epithelial organization10.1073/pnas.0704677104 ↗
23. Modeling ewing sarcoma tumors in vitro with 3D scaffolds10.1073/pnas.1221403110 ↗
24. Engineering tumors with 3D scaffolds10.1038/nmeth1085 ↗
25. Bioengineered 3D platform to explore cell-ECM interactions and drug resistance of epithelial ovarian cancer cells10.1016/j.biomaterials.2010.07.064 ↗
26. Hyaluronan (HA) interacting proteins RHAMM and hyaluronidase impact prostate cancer cell behavior and invadopodia formation in 3D HA-based hydrogels10.1371/journal.pone.0050075 ↗
27. Hyaluronic acid-based hydrogels as 3D matrices for in vitro evaluation of chemotherapeutic drugs using poorly adherent prostate cancer cells10.1016/j.biomaterials.2009.07.054 ↗
28. HYAL1 hyaluronidase in prostate cancer: a tumor promoter and suppressor10.1158/0008-5472.CAN-05-1022 ↗
29. Stromal and epithelial expression of tumor markers hyaluronic acid and HYAL1 hyaluronidase in prostate cancer10.1074/jbc.M008432200 ↗
30. Angiogenesis in a delayed revascularization model is accelerated by angiogenic oligosaccharides of hyaluronan
31. Amphiphilic block co-polyesters bearing pendant cyclic ketal groups as nanocarriers for controlled release of camptothecin10.1163/092050610X504260 ↗
32. Nonaqueous biocatalytic synthesis of new cytotoxic doxorubicin derivatives: exploiting unexpected differences in the regioselectivity of salt-activated and solubilized subtilisin10.1021/ja015977y ↗
33. The spreading, migration and proliferation of mouse mesenchymal stem cells cultured inside hyaluronic acid hydrogels10.1016/j.biomaterials.2010.08.103 ↗
34. Disulfide cross-linked hyaluronan hydrogels10.1021/bm025603c ↗
35. Hyaluronic acid-based microgels and microgel networks for vocal fold regeneration10.1021/bm0604956 ↗
36. Heparin-decorated, hyaluronic acid-based hydrogel particles for the controlled release of bone morphogenetic protein 210.1016/j.actbio.2011.04.018 ↗
37. Multistage nanoparticle delivery system for deep penetration into tumor tissue10.1073/pnas.1018382108 ↗
38. Reversal effect of tyroservatide (YSV) tripeptide on multi-drug resistance in resistant human hepatocellular carcinoma cell line BEL-7402/5-FU10.1016/j.canlet.2008.04.033 ↗
39. Dexamethasone-loaded block copolymer nanoparticles induce leukemia cell death and enhance therapeutic efficacy: a novel application in pediatric nanomedicine10.1021/mp300350e ↗
40. A methodology to study intracellular distribution of nanoparticles in brain endothelial cells10.1016/j.ijpharm.2005.03.030 ↗
41. Nile red: a selective fluorescent stain for intracellular lipid droplets10.1083/jcb.100.3.965 ↗
42. Diffusion and convection in collagen gels: implications for transport in the tumor interstitium10.1016/S0006-3495(02)73933-7 ↗
43. The delivery of doxorubicin to 3-D multicellular spheroids and tumors in a murine xenograft model using tumor-penetrating triblock polymeric micelles10.1016/j.biomaterials.2010.06.004 ↗
44. Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector10.1158/0008-5472.CAN-05-2242 ↗
45. Superior penetration and retention behavior of 50 nm gold nanoparticles in tumors10.1158/0008-5472.CAN-12-2071 ↗
46. Size-dependent localization and penetration of ultrasmall gold nanoparticles in cancer cells, multicellular spheroids, and tumors in vivo10.1021/nn301282m ↗
47. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery10.1016/j.biomaterials.2006.09.047 ↗
48. Enhanced percolation and gene expression in tumor hypoxia by PEGylated polyplex micelles10.1038/mt.2009.119 ↗
49. In situ crosslinkable hyaluronan hydrogels for tissue engineering10.1016/j.biomaterials.2003.08.014 ↗
50. Rheological characterization of in situ cross-linkable hyaluronan hydrogels10.1021/bm050361c ↗
51. Role of tumor-host interactions in interstitial diffusion of macromolecules: cranial vs. subcutaneous tumors10.1073/pnas.081626898 ↗
52. Multidrug resistance in cancer: role of ATP-dependent transporters10.1038/nrc706 ↗
53. The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump10.1073/pnas.91.19.8822 ↗
54. Structural and functional properties of human multidrug resistance protein 1 (MRP1/ABCC1)10.2174/092986711794839197 ↗
55. Lung resistance-related protein/major vault protein and vaults in multidrug-resistant cancer10.1097/00001622-200011000-00007 ↗
56. Multidrug resistance and the lung resistance-related protein in human colon carcinoma SW-620 cells10.1093/jnci/91.19.1647 ↗
57. Role of the lung resistance-related protein (LRP) in the drug sensitivity of cultured tumor cells10.1016/S0887-2333(02)00035-8 ↗
58. Early multidrug resistance, defined by changes in intracellular doxorubicin distribution, independent of P-glycoprotein10.1038/bjc.1991.413 ↗
59. Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines10.1002/(SICI)1097-0215(19960117)65:2<230::AID-IJC17>3.0.CO;2-H ↗
60. Multicellular spheroids as an in vitro tumor model10.1016/S0304-3835(98)00198-0 ↗
61. Star-shape copolymer of lysine-linked di-tocopherol polyethylene glycol 2000 succinate for doxorubicin delivery with reversal of multidrug resistance10.1016/j.biomaterials.2012.06.019 ↗
62. Bypassing multidrug resistance in cancer cells with biodegradable polymer capsules10.1002/adma.201003162 ↗